Wanhua Zhang1, Pu Kuang1, Ting Liu1. 1. a Department of Haematology , West China Hospital, Sichuan University , Chengdu , P.R. China.
Abstract
BACKGROUND: Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) genes are frequently altered in acute lymphoblastic leukaemia (ALL) patients. The aim of this meta-analysis was to comprehensively assess the prognostic value of CDKN2A/B deletions in ALL patients. METHODS: Systematic literature review was conducted in PubMed, Embase and Cochrane databases up to July 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with fixed-effects or random-effects models. RESULTS: A total of thirteen studies including 2857 patients were eligible for this meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 2.16, 95% CI 1.73-2.69). The adverse impact remained significant in both adult and paediatric ALL patients, and also in subgroups by ethnicity, ALL type, detection method of CDKN2A/B deletions, statistical method and endpoint. CONCLUSIONS: Our findings suggested that CDKN2A/B deletions were associated with poor prognosis independently in both adult and childhood ALL patients. Inclusion of CDKN2A/B status may further improve the risk stratification of ALL patients. Key Messages Although numerous studies have explored the prognostic significance of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions in acute lymphoblastic leukaemia (ALL) patients, the results remain conflicting. In this meta-analysis, we found that CDKN2A/B deletions were independent poor prognostic markers for both adult and paediatric ALL patients. Our findings justify the inclusion of CDKN2A/B status in the risk stratification of ALL patients.
BACKGROUND:Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) genes are frequently altered in acute lymphoblastic leukaemia (ALL) patients. The aim of this meta-analysis was to comprehensively assess the prognostic value of CDKN2A/B deletions in ALL patients. METHODS: Systematic literature review was conducted in PubMed, Embase and Cochrane databases up to July 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with fixed-effects or random-effects models. RESULTS: A total of thirteen studies including 2857 patients were eligible for this meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 2.16, 95% CI 1.73-2.69). The adverse impact remained significant in both adult and paediatric ALL patients, and also in subgroups by ethnicity, ALL type, detection method of CDKN2A/B deletions, statistical method and endpoint. CONCLUSIONS: Our findings suggested that CDKN2A/B deletions were associated with poor prognosis independently in both adult and childhood ALL patients. Inclusion of CDKN2A/B status may further improve the risk stratification of ALL patients. Key Messages Although numerous studies have explored the prognostic significance of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions in acute lymphoblastic leukaemia (ALL) patients, the results remain conflicting. In this meta-analysis, we found that CDKN2A/B deletions were independent poor prognostic markers for both adult and paediatric ALL patients. Our findings justify the inclusion of CDKN2A/B status in the risk stratification of ALL patients.
Authors: L J C M van Zutven; E van Drunen; J M de Bont; M M Wattel; M L Den Boer; R Pieters; A Hagemeijer; R M Slater; H B Beverloo Journal: Leukemia Date: 2005-07 Impact factor: 11.528
Authors: Faiyaz Notta; Charles G Mullighan; Jean C Y Wang; Armando Poeppl; Sergei Doulatov; Letha A Phillips; Jing Ma; Mark D Minden; James R Downing; John E Dick Journal: Nature Date: 2011-01-20 Impact factor: 49.962
Authors: Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Sarina Sulong; Anthony V Moorman; Julie A E Irving; Jonathan C Strefford; Zoe J Konn; Marian C Case; Lynne Minto; Kerry E Barber; Helen Parker; Sarah L Wright; Adam R M Stewart; Simon Bailey; Nick P Bown; Andrew G Hall; Christine J Harrison Journal: Blood Date: 2008-10-06 Impact factor: 22.113
Authors: Dianne Pulte; Lina Jansen; Adam Gondos; Alexander Katalinic; Benjamin Barnes; Meike Ressing; Bernd Holleczek; Andrea Eberle; Hermann Brenner Journal: PLoS One Date: 2014-01-27 Impact factor: 3.240
Authors: David O'Connor; Amir Enshaei; Jack Bartram; Jeremy Hancock; Christine J Harrison; Rachael Hough; Sujith Samarasinghe; Claire Schwab; Ajay Vora; Rachel Wade; John Moppett; Anthony V Moorman; Nick Goulden Journal: J Clin Oncol Date: 2017-11-13 Impact factor: 44.544
Authors: Beatriz Rosales-Rodríguez; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré; Haydeé Rosas-Vargas Journal: Curr Oncol Rep Date: 2020-11-14 Impact factor: 5.075
Authors: Yinghuan Dai; Ping Liu; Wenlong He; Lizhen Yang; Yang Ni; Xuejiao Ma; Furong Du; Chao Song; Yang Liu; Yi Sun Journal: Front Oncol Date: 2022-06-16 Impact factor: 5.738
Authors: Tomas Arpas; Hana Jelinkova; Stepan Hrabovsky; Martina Orsulova; Zuzana Vrzalova; Veronika Navrkalova; Eva Brhelova; Lenka Bryjova; Alena Bulikova; Eva Ondrouskova; Marketa Sejnohova; Frantisek Folber; Petra Sedová; Jiri Mayer; Sarka Pospisilova; Marie Jarosova; Michael Doubek Journal: Clin Case Rep Date: 2022-03-03
Authors: Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White Journal: Front Cell Dev Biol Date: 2022-07-12
Authors: Karen L Bride; Hai Hu; Anastasia Tikhonova; Tori J Fuller; Tiffaney L Vincent; Rawan Shraim; Marilyn M Li; William L Carroll; Elizabeth A Raetz; Iannis Aifantis; David T Teachey Journal: Haematologica Date: 2022-08-01 Impact factor: 11.047